1. Everitt, E. and Wohlfart, C., Spectrophotometric quantitation of anchorage-dependent cell numbers extraction of naphthol blue-black-stained cellular protein.Anal. Biochem., 162(1), 122–9 (1987).
2. Grindey, G. B., Boder, G. B., Grossman, C. S., Howbert, J. J., Poore, G. A., Shaw, W. H., Todd, G. C., and Worzalla, J. F., Further development of diarglsulfonylureas as novel anticancer drugs.Proc. Am. Assoc. Cancer Res., 28, 309 (1987).
3. Grindey, G. B., Identification of diarysulfonylureas as novel anticancer drugs.Proc. Am. Assoc. Cancer Res., 29, 535 (1988).
4. Grindey, G. B., Current status of cancer drug development: Failure or limited success.Cancer Cells, 2, 163–171 (1990).
5. Hainsworth, J. D., Handle, K. R., Satterlee, W. G., Kuttesch, J., Johnson, D. H., Grindey, G. B., Jackson, L. E., and Greco, F. A., Phase I clinical study of N-[(4-chlorophenylamino)]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).Cancer Res., 49, 5217–5220 (1989).